Clinical trials of antibody drugs in the treatments of atopic dermatitis

Guihao Zhou; Yueyao Huang; Ming Chu

doi:10.3389/fmed.2023.1229539

Clinical trials of antibody drugs in the treatments of atopic dermatitis

Front Med (Lausanne). 2023 Sep 4:10:1229539. doi: 10.3389/fmed.2023.1229539. eCollection 2023.

Authors

Guihao Zhou¹, Yueyao Huang¹, Ming Chu¹

Affiliation

¹ Department of Immunology, School of Basic Medical Sciences, National Health Commission (NHC) Key Laboratory of Medical Immunology, Peking University, Beijing, China.

Abstract

Atopic dermatitis (AD) is one of the most common, relapsing, chronic inflammatory skin disease, being regarded as a global health issue. Recent studies have shown that Th2 cell-mediated type 2 immunity plays a central role in AD. The type 2 inflammatory cytokines such as IL-4, IL-13, IL-22, IL-31, IL-17 and IL-5 mediate the pathogenesis of AD. A variety of antibody drugs targeting these cytokines have been developed to treat AD in clinics. Notably, several antibody drugs have exhibited high efficacy in treating atopic dermatitis in previous studies, demonstrating that they could be therapeutic methods for AD patients. Herein, we reviewed the clinical trials of antibody drugs in the treatment of AD, which provides a useful guideline for clinicians to treat patients with AD in clinics.

Keywords: antibody drugs; atopic dermatitis; clinical trials; dupilumab; tralokinumab.

Publication types

Review